Study Enrollment

Your details will not be published or shared.

Clinical Trial

S1929, “Phase II Randomized Study of Maintenance Atezolizumab versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)”

Eligibility Criteria

  • Confirmed diagnosis of extensive stage small cell lung cancer (ES-SCLC) No prior immunotherapy for ES-SCLC No prior investigational treatment of ES-SCLC. Participants must be ? 18 years of age

Contact Information

    Angela Goebel

    (706) 721-2388